Lantheus weighs potential $7 billion sale after Curium's offer, Bloomberg News reports
Lantheus Holdings (NASDAQ:LNTH) is reportedly considering a potential sale after receiving a takeover offer from private-equity backed Curium Pharma. The offer values Lantheus at approximately $7 billion, according to a Bloomberg News report published on Friday, May 22, citing individuals familiar with the matter.
The two companies have been engaged in discussions regarding a potential deal. The Bloomberg report indicated that a transaction could be weeks away. However, no final decision has been made, and there is no assurance that the talks will culminate in a transaction.
Curium Pharma, which is backed by private equity, was valued at about $7 billion last year. This valuation occurred when its owner, CapVest Partners, raised funds for a continuation vehicle specifically for the nuclear medicine company, Bloomberg News reported.
Lantheus and Curium did not immediately respond to Reuters' requests for comment regarding the reported discussions.
Shares of Lantheus Holdings have seen a significant increase this year, gaining 54.8% year-to-date. The company currently holds a market capitalization of approximately $6.15 billion.